Cover Image
市場調查報告書

慢性骨髓性白血病:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析

Chronic myeloid leukemia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis

出版商 Datamonitor Healthcare 商品編碼 365176
出版日期 內容資訊 英文 219 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
慢性骨髓性白血病:流行病學·基於患者的市場預測,治療流程,上市藥·開發平台藥物分析 Chronic myeloid leukemia: Epidemiology and patient-based market forecasts, treatment algorithm, and marketed and pipeline drug analysis
出版日期: 2016年05月01日 內容資訊: 英文 219 Pages
簡介

本報告提供慢性骨髓性白血病治療藥市場相關調查分析,提供您市場預測,治療,流行病學,上市藥,開發平台藥物趨勢等系統性資訊。

預測:慢性骨髓性白血病

  • 摘要整理
  • 市場概要·趨勢
  • 手法·市場定義
  • Bosulif (bosutinib)
  • Gleevec (imatinib)
  • Iclusig (ponatinib)
  • imatinib Generics
  • Sprycel (dasatinib)
  • Synribo (omacetaxine mepesuccinate)
  • Tasigna (nilotinib)
  • 1次調查手法

治療:慢性骨髓性白血病

  • 摘要整理
  • 1次調查手法
  • 疾病定義·診斷
  • 患者區分
  • 各國治療樹
  • 目前治療選擇
  • 處方趨勢
  • 未滿足需求

流行病學:美國·日本·EU5個國家的慢性骨髓性白血病

  • 摘要整理
  • 疾病定義
  • 存活率
  • 全球變動
  • 危險因素
  • 合併症
  • 資訊來源·手法
  • 預測
  • 流行病學者的考察
  • 優點·缺點
  • 參考文獻

上市藥:慢性骨髓性白血病

  • 摘要整理
  • 產品概要
  • 產品簡介:Bosulif
  • 產品簡介:Gleevec
  • 產品簡介:Iclusig
  • 產品簡介:Sprycel
  • 產品簡介:Synribo
  • 產品簡介:Tasigna

開發平台:慢性骨髓性白血病

  • 摘要整理
  • 開發平台趨勢

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: DMKC5889

Sprycel and Tasigna continue to compete for market share in second-line CML as generic imatinib begins to supersede Gleevec in all markets.

This report addresses the following questions:

  • What are the biggest unmet needs in the CML market?
  • What are the current pipeline trends in the CML market and how do they compare to other hematological malignancies?
  • How will generic imatinib impact revenues of Gleevec and the overall market value of CML?
  • What is the market potential for Sprycel and Tasigna and how will they compete with generic imatinib in the first-line setting?
  • How will Iclusig, Bosulif, and Synribocompete in later lines of therapy?

TABLE OF CONTENTS

FORECAST: CHRONIC MYELOID LEUKEMIA

  • 1. Executive Summary
  • 2. Market Overview and Trends
  • 3. Methodology and Market Definition
  • 4. Bosulif (bosutinib)
  • 5. Gleevec (imatinib)
  • 6. Iclusig (ponatinib)
  • 7. imatinib Generics
  • 8. Sprycel (dasatinib)
  • 9. Synribo (omacetaxine mepesuccinate)
  • 10. Tasigna (nilotinib)
  • 11. Primary Research Methodology

TREATMENT: CHRONIC MYELOID LEUKEMIA

  • 12. Executive Summary
  • 13. Primary Research Methodology
  • 14. Disease Definition and Diagnosis
  • 15. Patient Segmentation
  • 16. Country Treatment Trees
  • 17. Current Treatment Options
  • 18. Prescribing Trends
  • 19. Unmet Needs in Chronic Myeloid Leukemia

EPIDEMIOLOGY: CHRONIC MYELOID LEUKEMIA IN THE US, JAPAN, AND 5EU

  • 20. Executive Summary
  • 21. Disease Definition
  • 22. Survival
  • 23. Global Variation
  • 24. Risk Factors
  • 25. Co-Morbidities
  • 26. Sources and Methodology
  • 27. Forecast
  • 28. Epidemiologist Insight
  • 29. Strengths and Limitations
  • 30. Bibliography

MARKETED DRUGS: CHRONIC MYELOID LEUKEMIA

  • 31. Executive Summary
  • 32. Product Overview
  • 33. Product profile: Bosulif
  • 34. Product profile: Gleevec
  • 35. Product profile: Iclusig
  • 36. Product profile: Sprycel
  • 37. Product profile: Synribo
  • 38. Product profile: Tasigna

PIPELINE: CHRONIC MYELOID LEUKEMIA

  • 39. Executive Summary
  • 40. Pipeline Trends
Back to Top